Monday, November 2, 2026||
MultiKhabarMultiKhabar

Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand

Share:WhatsAppFacebookX (Twitter)Telegram
EXECUTIVE SUMMARY

Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.

Key Takeaways

  • Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand.
  • Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
  • Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.

Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.

Share:WhatsAppFacebookX (Twitter)Telegram

Read Complete Original Article

Published originally on CNBC Business

Visit Publisher Site →

Related News

🇺🇸 United States
The Danger Of Hanging On To A Bad Hire
Economy & Business1h ago

The Danger Of Hanging On To A Bad Hire

The cost of hanging on to a bad hire in a start-up or small company will be financially compromising and, more significantly, a royal pain on an emotional level.

Forbes Business
Multikhabar App

All Information In One Place

Real-time headlines from trusted sources. Get the app now — stay updated, inspired, and ahead with breaking news!

Get it on Google Play